Last edition
News about "China CDE"
GSK's RSV Vaccine Arexvy Accepted for Regulatory Review in China for Adults Aged 60 and Above
China’s drug regulator has accepted GSK’s Arexvy for review to prevent RSV-related lower respiratory tract disease in adults 60 and older, with a decision expected in 2027.
China CDE | 11/02/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members